Day: September 16, 2021

Interfor Amends Share Buyback Program

Interfor Amends Share Buyback Program

BURNABY, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) — INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX: IFP) announced today that the Toronto Stock Exchange (“TSX”) has accepted a notice filed by the Company of its intention to amend its normal course issuer bid (“NCIB”). The amended NCIB increases the maximum number of common shares that may be purchased by an additional 690,906 common shares, and results from a recalculation of the Company’s public float based on updated ownership information of certain insiders as of the date of the original announcement of the NCIB. The amended NCIB will allow for the purchase of up to 6,672,658 common shares during the twelve-month period that commenced on November 11, 2020 and ends on November 10, 2021, which represents 10% of the Company’s public float as at November 5, 2020....

Continue reading

Green Stream Holdings Management Discusses Progress In Its Initiative On Solar Feasibility Studies

Green Stream Holdings Management Discusses Progress In Its Initiative On Solar Feasibility Studies

Company Previously Announced Its 5th Solar Feasibility Study For Multi Mega Solar Farms With KMB Design Group: A Full Service Engineering Solutions Provider That Has Provided Designs And Engineering Services For Over 1,000 Projects Nationwide With Over 1,500 MW Of Solar Designed NEW YORK, NY, Sept. 16, 2021 (GLOBE NEWSWIRE) — Green Stream Holdings Inc. (OTC PINK: GSFI) (“the Company”) (https://greensolarutility.com), an emerging leader in the solar utility and finance space, today commentated on its 5th feasibility study site and 5th agreement with property owners of host sites. CEO James DiPrima said: “As technology costs have fallen and efficiencies have increased, providing more energy output per square foot, solar has become one of the primary sources of new electrical capacity installed across the United States. As...

Continue reading

Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement

Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement

Sight Sciences Seeks Injunction Related to Hydrus® Microstent’s Infringement MENLO PARK, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis, Inc. for infringement of U.S. Patent Numbers 8,287,482, 9,370,443, 9,486,361, and 10,314,742. These patents describe and claim devices and methods for reducing intraocular pressure in the eye. Sight Sciences’ complaint seeks an injunction to prevent the infringing manufacture, use and sale of the Hydrus® Microstent, along with money damages for past infringement. “We filed this lawsuit to protect and defend our commercial, market and intellectual property leadership positions within the field of canalicular glaucoma surgery,” said Paul Badawi, co-founder and CEO...

Continue reading

Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

– Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 – – Data support the use of toripalimab with chemotherapy as first-line therapy for patients with ESCC – – Coherus and Junshi Biosciences plan to submit a BLA supplement for 1L ESCC in 2022 – SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced positive interim results from the pivotal study “JUPITER-06” (NCT03829969), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with chemotherapy as a first-line therapy for patients with advanced or metastatic esophageal...

Continue reading

Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO

Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO

Objective response rate of 33% and median duration of response not reached with 19.4 months median follow-up in PD-L1+ tumors; expands benefit of anti-PD-1 alone Improved responses seen across all histology subgroups including populations of patients unresponsive to other therapies Dr. David O’Malley to present data in an oral presentation on Sept. 19th LEXINGTON, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO) Virtual Conference 2021 in an abstract titled Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4):...

Continue reading

Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021

Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021

New quality of life data for 177Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to standard of care alone1  US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to 177Lu-PSMA-617; Submission to FDA and European Medicines Agency on track for 2H21  Novartis committed to reimagining prostate cancer with targeted radioligand therapy; two Phase III studies with 177Lu-PSMA-617 in earlier lines of treatment ongoing with goal to investigate earlier stages of disease Basel, September 17, 2021 — Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational...

Continue reading

Zogenix Reports Granting of Inducement Awards

Zogenix Reports Granting of Inducement Awards

EMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) — Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen (14) new employees. The awards were made on September 15, 2021, under Zogenix’s 2021 Employment Inducement Equity Incentive Award Plan, which was approved by the company’s board of directors under Nasdaq Marketplace Rule 5635(c)(4), for granting equity awards to new employees of Zogenix as an inducement to join the company. The awards consist of options to purchase an aggregate of 45,100 shares of Zogenix common stock and 22,600 restricted stock units. The options have a ten year term and an exercise price equal to $14.69, the closing price per share of the common stock on the grant date, and vest over a four-year period, with 25% of...

Continue reading

Methanex Announces a 5% Share Repurchase Program

Methanex Announces a 5% Share Repurchase Program

VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) — Methanex Corporation (the “Company” or “Methanex”) (TSX:MX) (NASDAQ:MEOH) announced today that its Board of Directors has approved a Normal Course Issuer Bid (“NCIB”) whereby the Company will purchase for cancellation up to 3,810,464 common shares (“Shares”), representing 5% of the 76,209,280 Shares issued and outstanding as of September 16, 2021. Purchases under the NCIB will commence on September 24, 2021 and end no later than September 23, 2022. Purchases will be made from time to time at the then current market price of the Shares and all Shares purchased under the NCIB will be cancelled. John Floren, President and CEO of Methanex commented, “We are pleased to announce a new share repurchase program which builds on our long track record of returning...

Continue reading

HUMBL Announces Launch of HUMBL Tickets Platform

HUMBL Announces Launch of HUMBL Tickets Platform

San Diego, California, Sept. 16, 2021 (GLOBE NEWSWIRE) — HUMBL, Inc. (OTC Markets: HMBL) announced today the launch of the HUMBL Tickets™ platform to provide consumers with direct access to lower-cost, premium seating options across verticals such as pro sports, college sports, concerts, theater, festivals, and more. HUMBL Tickets customers will receive 100% customer protection on authenticated inventory, safe and secure transactions that encrypt and protect personal data and information, as well as end-to-end customer support representatives available by phone and email channels. “I want to thank our teams, who worked hard to deploy a scalable ticket solution that will push forward an industry in strong need of technological and pricing disruption,” said Brian Foote, CEO of HUMBL. HUMBL Tickets will also collaborate with its HUMBL...

Continue reading

ADT to Participate in the Goldman Sachs 30th Annual Communacopia Conference

ADT to Participate in the Goldman Sachs 30th Annual Communacopia Conference

BOCA RATON, Fla., Sept. 16, 2021 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT), the most trusted brand in smart home and small business security, announced today that Jim DeVries, ADT’s President and Chief Executive Officer, will participate in the Goldman Sachs 30th Annual Communacopia Conference on Thursday, Sept. 23, 2021. DeVries will participate in a fireside chat, which will begin at approximately 11:20 AM EDT. A live webcast of the virtual event, as well as a replay following the presentation, will be available through the ADT investor relations website at investor.adt.com. About ADT Inc. ADT is the most trusted brand in smart home and small business security. Through innovative products, partnerships and the largest network of smart home security professionals in the United States, we connect and protect what matters most to...

Continue reading